Could a simple urine test spare bladder cancer patients from chemotherapy?

NCT ID NCT07749924

Not yet recruiting Disease control Sponsor: Tianjin Medical University Second Hospital Source: ClinicalTrials.gov ↗

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This trial asks whether some people with intermediate-risk bladder cancer can safely skip chemotherapy after having their tumor removed. Doctors will use a urine test before surgery to find patients whose tumors are unlikely to shed detectable signals. These patients will then be randomly assigned to either standard chemotherapy placed into the bladder or active surveillance with regular check-ups. The goal is to see if active surveillance keeps the cancer from coming back just as well as chemotherapy, without the extra treatment burden.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Active surveillance (no drug) versus adjuvant intravesical chemotherapy (gemcitabine or mitomycin C)
What this could lead to: If active surveillance proves as effective as chemotherapy, many patients could avoid the discomfort and side effects of bladder instillations without raising their risk of recurrence.
What could go wrong: This is an early-stage trial, and skipping chemotherapy might increase the chance of the cancer coming back in some patients. The urine test used to select patients is not perfect, so some may still benefit from chemo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-invasive bladder urothelial carcinoma Non-Muscle Invasive Bladder Neoplasms superficial urinary bladder carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)

Contacts and locations

Locations

Daqing Oil General Hopital

Daqing, China
General Hospital of Tianjin Medical University

Tianjin, China
Nanchang Second People's Hospital

Nanchang, China
The Second Hospital of Tianjin Medical University

Tianjin, 300000, China
Tianjin Hospital

Tianjin, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.